MYTAY yields 24.15% · PFE yields 6.13%● Live data
📍 MYTAY pulled ahead of the other in Year 1
Combined, MYTAY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYTAY + PFE for your $10,000?
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság provides fixed-line and mobile telecommunication services for residential and small business customers in Hungary, Bulgaria, Romania, and the Republic of North Macedonia. The company operates in MT-Hungary and North Macedonia segments. It offers TV distribution, information communication, and system integration services; mobile telecommunication services, such as prepaid and postpaid plans, data plans, TV, broadband, SMS, and phone services; internet and voice, Office 365, server and data park, and machine to machine services; and sells telecommunications network and equipment. The company also provides mobile services comprising mobile tariff plans and mobilnet; IT services, including modern office, business support and security, communication solutions, IT devices, servers, and data pack services; and IoT services and data transmission solutions. In addition, it offers fixed line wholesale services comprising access, IP and data, voice, and TV services; mobile wholesale services, such as mobile interconnect and interworking products, and roaming services; international wholesale voice and data services, as well as IPv6 dual-stack services to its residential customers. Further, the company provides system integration and IT services, as well as operates as an interactive service provider of telecommunications applications and telebikes community. It offers its services under the Telekom and T-Systems brands. The company was incorporated in 1991 and is headquartered in Budapest, Hungary. Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság is a subsidiary of Deutsche Telekom Europe B.V.
Full MYTAY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.